Thai CL Policy Estimated Worth $253 Million Over Five Years
This article was originally published in PharmAsia News
Thailand's policy decision regarding compulsory licensing for key foreign drugs could be worth $253.2 million to the nation over the next five years, the government has estimated. A committee considering whether to keep or drop the compulsory licensing policy is expected to submit the estimate to the Public Health Ministry. The figure is based in part on estimates of the number of new cancer cases expected to be reported this year through 2012. (Click here for more
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.